Mankind Pharma shows up in
58%
Mankind Pharma appears in 33% of buyer questions and 100% of direct comparison questions that include Mankind Pharma. Cipla appears in 83% of buyer questions.
AI search report
See where Mankind Pharma is losing buyers in AI search
See when AI mentions Mankind Pharma, where buyer questions leave you out, and what to fix first so more buyers discover you before competitors.
What buyers see in AI search
What AI says before buyers reach Mankind Pharma's site
Buyer questions missed
42%
Mankind Pharma is left out of 42% of the buyer and comparison questions checked.
Who AI recommends instead
Cipla
Cipla is the competitor AI surfaces most often here.
Where AI already picks you
AI does not consistently connect Mankind Pharma with a clear reason buyers would choose it yet. That usually means the evidence buyers need is either missing, scattered, or easier to find on competitor sites.
Where competitors beat you
- Competitors beat Mankind Pharma on Acute Therapy Coverage. Cipla is rated moderate while Mankind Pharma is limited.
- Competitors beat Mankind Pharma on Branded Generics Portfolio. Sun Pharmaceutical Industries is rated moderate while Mankind Pharma is limited.
- Competitors beat Mankind Pharma on Chronic Disease Coverage. Cipla is rated strong while Mankind Pharma is limited.
How AI describes you vs competitors
What AI connects each brand with
| What buyers care about | What this means | Mankind Pharma | Sun Pharmaceutical Industries | Cipla | Dr. Reddy's Laboratories |
|---|---|---|---|---|---|
| Integrations | AI gives Dr. Reddy's Laboratories more credit for integrations than Mankind Pharma. | Barely associated | Barely associated | Barely associated | Sometimes associated |
| Pricing | AI has little clear evidence connecting Mankind Pharma with pricing. | Barely associated | Barely associated | Barely associated | Barely associated |
| Branded Generics Portfolio | AI gives Sun Pharmaceutical Industries more credit for branded generics portfolio than Mankind Pharma. | Barely associated | Sometimes associated | Barely associated | Barely associated |
| Chronic Disease Coverage | AI gives Cipla more credit for chronic disease coverage than Mankind Pharma. | Barely associated | Sometimes associated | Clearly associated | Barely associated |
| Acute Therapy Coverage | AI gives Cipla more credit for acute therapy coverage than Mankind Pharma. | Barely associated | Barely associated | Sometimes associated | Barely associated |
| Who-gmp Certification | AI gives Sun Pharmaceutical Industries more credit for who-gmp certification than Mankind Pharma. | Barely associated | Sometimes associated | Barely associated | Barely associated |
Buyer questions you are missing
The questions where buyers may never see Mankind Pharma
These are high-intent questions where AI did not mention Mankind Pharma. Each one can become a clear answer page AI can trust and reuse, supported by evidence from Mankind Pharma's site.
Buyer question
Where can I find a reliable Indian pharma manufacturer that supplies prescription drugs to hospitals and clinics in bulk?
Mankind Pharma was not mentioned in this AI answer.
See the AI answerBuyer question
What are the best vertically integrated pharmaceutical companies in India for veterinary prescription medicines?
Mankind Pharma was not mentioned in this AI answer.
See the AI answerBuyer question
Are there Indian pharma companies that provide prescription antibiotics and other medicines directly to farmers for livestock treatment?
Mankind Pharma was not mentioned in this AI answer.
See the AI answerBuyer question
How do I evaluate Indian prescription medicine suppliers for institutional procurement in government hospitals?
Mankind Pharma was not mentioned in this AI answer.
See the AI answerComparison question
Cipla vs Sun Pharmaceutical Industries institutional investor appeal in Indian pharma sector
Mankind Pharma was not mentioned in this AI answer.
See the AI answerWhat to fix first
The shortest path to better AI search presence
Readable turns missed buyer questions into pages AI can trust, clearer evidence buyers can verify, and comparison answers that make it easier for AI tools to recommend you.
Close the Acute Therapy Coverage gap before competitors keep winning the recommendation.: Buyers are asking about Acute Therapy Coverage, but your homepage barely explains it. AI answers currently connect Cipla more strongly with that need.
Create dedicated comparison landing pages (e.g., 'Mankind Pharma vs Sun Pharma for institutional procurement') that explicitly document WHO-GMP certifications, CMSS/GeM empanelment status, and NPPA-compliant pricing to become citable sources in AI institutional supply responses.
Publish structured, data-rich content on IQVIA/AIOCD AWACS market share, stockist count, and Tier 2–4 field force metrics—sources AI already cites for distribution queries—so Mankind's rural penetration credentials are directly attributable in category-level AI recommendations.
Develop chronic disease and affordability-focused category pages that explicitly compare Mankind's branded generic price points against DPCO schedules and Jan Aushadhi listings, positioning the brand as a primary recommendation rather than a secondary mention in diabetes and hypertension queries.
In bulk institutional procurement queries, Sun Pharma and Cipla are recommended as primary suppliers while Mankind Pharma is entirely absent, despite its scale and distribution network qualifying it for this segment.
What you’ll see in the AI search review
Find the AI answers costing you buyers
In one review, we’ll show where Mankind Pharma is missing, which competitors AI is recommending instead, and the first pages or evidence updates most likely to help you show up.
The buyer questions where Mankind Pharma is left out.
The competitor claims AI is repeating instead.
The first fixes most likely to help Mankind Pharma show up.
Fix the buyer moments AI is missing
We’ll show you which AI answers are costing you buyers and what to publish first.
Bring this report to a short review with Readable. You will leave knowing the buyer questions, evidence gaps, and answer pages that matter most.
Improve my AI visibility